GLP-1 Education
Evidence, care, and useful questions
31 complete articles for Brown Virtual Lab. Explore treatment questions, interpret evidence, and bring focused questions into the next conversation.
SELECT in Practice: Discussing Cardiovascular Evidence with Precision
Translate a cardiovascular outcomes trial into a careful patient conversation and a documented clinical decision.
039FLOW and Kidney Care: Connecting Evidence to a Clinical Monitoring Plan
Use kidney outcomes evidence alongside an accurate baseline and coordinated longitudinal care.
040STEP-HFpEF: Bring Symptoms and Daily Function into the Treatment Conversation
Use patient reported outcomes thoughtfully when assessing obesity related HFpEF care.
041SUMMIT: Reading Tirzepatide Evidence Through the HFpEF Clinical Lens
Identify the population, endpoint, and individual care questions before applying trial evidence.
042LEADER and the Importance of Medication Specific Cardiovascular Evidence
Use a landmark liraglutide trial to strengthen the precision of cardiometabolic counseling.
043REWIND: Use Trial Eligibility to Improve Cardiovascular Counseling
Examine population and endpoint differences before transferring a research result into clinical practice.
051How Randomization Strengthens a GLP-1 Treatment Question
Randomization creates treatment groups through a chance process.
052What an Observational GLP-1 Study Can Teach Us
Observational studies examine treatment as it occurs in practice.
053Translate Relative Risk Into Absolute Numbers
Relative measures describe proportional differences between groups.
054Read a Confidence Interval With Clinical Judgment
A confidence interval communicates statistical uncertainty around an estimate under the analysis assumptions.
055Understand a Hazard Ratio in a GLP-1 Outcomes Trial
A hazard ratio compares modeled event rates over follow-up.
056Why GLP-1 Trial Eligibility Matters
Eligibility criteria describe the people for whom a trial directly supplies evidence.
057Separate a Primary Endpoint From an Exploratory Finding
A primary endpoint anchors the main study question and sample size planning.
058What a Composite Cardiovascular Endpoint Means
A composite endpoint combines several defined events into a single outcome.
059How to Read a GLP-1 Subgroup Analysis
Subgroup analyses explore whether treatment effects vary across participant characteristics.
060Weight Change and Cardiovascular Events Answer Different Questions
Weight change is a measurable treatment outcome with its own clinical meaning.
061How to Appraise an Emerging GLP-1 Hair Loss Signal
A hair loss signal begins with a defined observation and a question about its explanation.
062Scalp Symptoms During GLP-1 Therapy: Build a Better Research Question
Scalp itching or redness is a symptom description that may encompass several conditions.
063Nail Changes and GLP-1 Medicines: Design an Informative Study
Nail lifting, discoloration, brittleness, and altered growth describe different outcomes.
064What a Spontaneous Safety Report Contributes
Spontaneous reports bring clinical concerns to safety surveillance, including experiences outside trial populations.
065Why a Disproportionality Signal Needs Follow-Up
Disproportionality analysis examines whether a drug-event combination appears more often in a reporting database than expected under the chosen comparison method.
066Turn a GLP-1 Case Report Into a Useful Research Question
A case report can preserve the detail of an unusual clinical experience.
067Read a GLP-1 Systematic Review Through Its Search Methods
A systematic review begins with a defined question and an explicit search.
068Understand Heterogeneity Before Trusting a Pooled Estimate
Studies can differ in participants, doses, comparison treatments, outcome definitions, follow-up, and analysis.
069Recognize Confounding by Indication in GLP-1 Research
Confounding by indication occurs when the reason for receiving treatment also relates to the outcome.
070Prevent Timeline Errors in a GLP-1 Cohort
A cohort study needs a clear starting point shared by the treatment groups.
071Read Missing Data as Part of the GLP-1 Story
Missing measurements can arise when people miss visits, stop treatment, change care settings, or leave a study.
072Why Representation Matters in GLP-1 Evidence
Research representation concerns whether the participants and care settings reflect the people who may use an intervention.
073Distinguish GLP-1 Efficacy From an Implementation Question
An efficacy question examines treatment outcomes under a defined study design.
074Make Patient Experience a Measurable GLP-1 Research Outcome
Patient experience can include symptom burden, treatment inconvenience, confidence with medication use, and the effect of care on daily life.
075Build a Living GLP-1 Evidence Brief
A living evidence brief keeps a clinical or educational summary aligned with new information.